ArticlePlastic and reconstructive surgery. Global open2026
Effects of New Cellular Treatment Factor and Human Exosome Injection on Intact Skin Regeneration in a Randomized In Vivo Study.
Article in Plastic and reconstructive surgery. Global open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Enhancing intact skin regeneration is a growing focus in dermatology and aesthetics. Human derived exosomes and mesotherapy formulations such as New Cellular Treatment Factor (NCTF) have shown regenerative potential, yet their combined effects on healthy skin remain unstudied. This study evaluated NCTF, two exosome products, and their combinations on markers of skin regeneration. Methods: A randomized, within-animal controlled study was conducted in 144 adult male Syrian golden hamsters. Each animal received 6 intradermal injections on the dorsum: saline control, CellExosome, ASCE+ Exosome, NCTF, NCTF + CellExosome, or NCTF + ASCE+ Exosome. Skin biopsies were obtained at baseline and on days 3, 7, and 14. Histological assessments (hematoxylin and eosin, Van Gieson, Masson trichrome) evaluated dermal structure and collagen deposition. CD34 immunohistochemistry quantified microvascular density. Results: By day 14, collagen synthesis and vascular proliferation were significantly greater in all active treatment groups compared with the control ( Conclusions: NCTF and human-derived exosomes enhance dermal structural regeneration and angiogenesis in intact skin. Combination therapy, particularly NCTF + CellExosome, provides the strongest regenerative response, supporting further investigation for clinical aesthetic applications.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.